ArticleJournal of thoracic disease2026
Epidemiological patterns of pulmonary hypertension at 3,658 meters: insights from a Tibet plateau retrospective study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High altitude environment exerts a significant impact on the pathophysiology of various types of pulmonary hypertension, yet the clinical characteristics of pulmonary hypertension in high altitude areas remain unclear. The purpose of this study was to clarify the type distribution and clinical features of pulmonary hypertension in high-altitude regions. Methods: A retrospective study was conducted. Consecutive inpatients who underwent complete Doppler echocardiography and were diagnosed with pulmonary hypertension at the People's Hospital of Xizang Autonomous Region from January 2014 to January 2019 were enrolled. Their demographic data, etiological information, laboratory indicators and echocardiographic parameters were collected. Patients were divided into five groups according to clinical classification criteria, and the differences among the groups were compared. Results: A total of 312 patients with pulmonary hypertension were enrolled, with a mean age of 60±14 years, including 164 males (52.6%) and 148 females (47.4%). The subjects were predominantly of Zang ethnicity (295 cases, 94.6%), with a mean residential altitude of 3,865±409 meters. According to the World Health Organization (WHO) clinical classification, Group 3 accounted for the highest proportion (66.0%), followed by Group 2 (16.0%), Group 1 (12.8%), Group 5 (2.9%) and Group 4 (2.2%). The main etiologies were chronic obstructive pulmonary disease (COPD)/emphysema (31.1%) and high altitude pulmonary hypertension (HAPH) (29.5%). Patients in Group 3 had the highest proportion of males (62.1%), the oldest age and the highest smoking rate (39.8%), and their hemoglobin, hematocrit and red blood cell count were significantly higher than those in other groups (all P<0.01). Conclusions: Group 3 is the most common type of pulmonary hypertension in hospitalized patients in high-altitude areas, with the main etiologies being COPD/emphysema and HAPH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.